<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The impressive anti-inflammatory effects of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)alpha blockers etanercept and infliximab have led to their use in multiple <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> besides their original indication, <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) </plain></SENT>
<SENT sid="1" pm="."><plain>The well-studied clinical effects of both agents in RA are the reduction of signs and symptoms of <z:mp ids='MP_0002933'>joint inflammation</z:mp> as well as the arrest of bone destruction </plain></SENT>
<SENT sid="2" pm="."><plain>Infliximab has also been Food and Drug Administration-approved in the treatment of <z:e sem="disease" ids="C0010346" disease_type="Disease or Syndrome" abbrv="">Crohn disease</z:e>; etanercept is now FDA-approved for juvenile <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001369'>arthritis</z:hpo> and psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Favorable initial clinical trials have been reported in other <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e>, including <z:e sem="disease" ids="C0038013" disease_type="Disease or Syndrome" abbrv="">ankylosing spondylitis</z:e> and adult Still disease </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, TNF alpha blockade is being studied in the treatment of <z:hpo ids='HP_0000554'>uveitis</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, and <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Studies in <z:hpo ids='HP_0100806'>sepsis</z:hpo> and septic shock have identified small subsets of patients that may benefit from TNF alpha blockade, but broader use in septic patients has not improved survival </plain></SENT>
<SENT sid="6" pm="."><plain>The TNF alpha blockers have had relatively infrequent serious side effects, especially compared with the immunosuppressive and cytotoxic agents otherwise employed to treat these diseases </plain></SENT>
<SENT sid="7" pm="."><plain>Further studies of optimal dosing, combination with other therapies, and long-term benefits and side effects will emerge from future trials </plain></SENT>
</text></document>